Information Provided By: 
Fly News Breaks for February 22, 2018
ABMD
Feb 22, 2018 | 06:11 EDT
After hosting investor meetings with Abiomed management, Piper Jaffray analyst Matt O'Brien says "there is so much to like here." Management noted that the label expansions from last week were likely to expand the shock patient population by 20%-25%, O'Brien tells investors in a research note. He sees "significant room for growth" from Impella and keeps an Overweight rating on Abiomed shares with a $300 price target. The analyst continues to encourage investors to start or build positions.
News For ABMD From the Last 2 Days
There are no results for your query ABMD
